Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.44
+2.192.06%
Pre-market: 108.00-0.4400-0.41%09:16 EDT
Volume:1.71M
Turnover:184.58M
Market Cap:12.31B
PE:32.06
High:109.63
Open:106.66
Low:105.50
Close:106.25
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.42
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.74
PE(LYR):42.36

Loading ...

Halozyme to Report Q2 Results After Market Close, Host Conference Call

Reuters
·
Jul 23

Halozyme Therapeutics Price Target Maintained with a $95.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 21

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Simply Wall St.
·
Jul 21

Positive Earnings Outlook and Low Prices Signal Buying Opportunity for Non-Ferrous Metals ETF, Highlighting HALO Trading, Computing Metals, and Strategic Metals

Deep News
·
Jul 21

Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug

MT Newswires Live
·
Jul 20

Halozyme announces global collaboration, license agreement with Incyte

TIPRANKS
·
Jul 20

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Eligible to Receive Royalties on Net Sales of Enhanze Medicines

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - to Receive Upfront Payment and Eligible for Milestone Payments from Incyte

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Incyte Granted Rights to Develop Enhanze with Mutcalr Program and Option for Two Additional Targets

THOMSON REUTERS
·
Jul 20

China's High-Barrier "HALO Assets" Offer Global Scarcity, Says Morgan Stanley Economist

Deep News
·
Jul 17

Halozyme CEO Helen Torley Disposes of 1,923 Common Shares Worth $146,852.55

Reuters
·
Jul 10

Goldman Sachs Revives "HALO Trade" Concept, Signaling a New Phase

Deep News
·
Jul 08

Halozyme Appoints David Ramsay as President Drug Delivery

Reuters
·
Jul 06

Stocks to Watch: Seer, Orthofix Medical, Halozyme Therapeutics

Dow Jones
·
Jul 03

Halozyme Director Bernadette Connaughton Sells 1,625 Shares Worth $124,370.63

Reuters
·
Jul 03

Halozyme Therapeutics Operating Chief Caudill to Exit

Dow Jones
·
Jul 03

Halozyme COO Cortney Caudill Departs Amid Senior Management Restructure

Reuters
·
Jul 03

Halozyme Director Mahesh Krishnan Disposes of 7,304 Shares for $547,800

Reuters
·
Jul 01